XERIMIS, Inc. Completes 3rd Expansion of Moorestown, NJ facility
Moorestown, New Jersey (U.S.A), 15 August 2007

Moorestown, NJ - Xerimis, Inc. announced the completion of its 3rd facility expansion since its inception in 2001. This expansion adds space for warehousing, distribution and returned product accountability, along with additional office space.

This expansion increases the total facility to 64,000 square feet; of which 14,600 square feet is dedicated cGMP warehouse, and nearly 2000 square feet is dedicated for refrigerated and frozen product warehousing.

This expansion is part of Xerimis' overall managed growth plan and represents our continued response to our clients' needs.

Xerimis is a privately held firm dedicated strictly to the packaging of clinical supplies for pharmaceutical, biotech and clinical research organizations in all phases of development.

XERIMIS, Inc. Announces Plan For Addition of Services For Controlled Substances.
Moorestown, New Jersey (U.S.A), 12 July 2006

In response to client demand, Xerimis has initiated plans for the introduction Controlled Substances capabilities. In the initial phase, currently pending DEA approval, Xerimis plans to offer full service packaging, labeling, distribution and return accountability for Schedule III - V materials. Xerimis plans to introduce Schedule II capabilities shortly after introduction of Phase I.

These enhancements to Xerimis' service offerings are in line with the company's managed growth plan. "I am very pleased with our continued growth at Xerimis and the introduction of new service offerings to the benefit of our clients," said Peter Bernardo, PhD, President and CEO of Xerimis Inc.

Xerimis is a privately held firm dedicated strictly to the packaging of clinical supplies for pharmaceutical, biotech and clinical research organizations in all phases of development.

XERIMIS, Inc. Announces Development of Custom Inventory System.
Moorestown, New Jersey (U.S.A), 01 October 2005

Xerimis, Inc. announced the start of the development for the first phase of an automated inventory system. When implemented, the automated inventory system will improve and streamline internal processes, as well as improve response time to inventory queries from clients.

The inventory system will utilize the latest hardware and custom software in order to provide the best experience to Xerimis' clients and employees. In addition, Xerimis plans to incorporate barcode production and barcode scanning technology with the goal of increasing the speed and accuracy of inventory data entry.

The first phase of the inventory system will include: tracking inventory items from receipt, through production, and into distribution; tracking of Xerimis-produced clinical labels; capture of quarantine/release status; tracking of expiration dates; and tracking of inventory location.

Xerimis also has plans to expand the capabilities of the inventory system through the implementation of several future phases. The following functionality will appear in future phases: tracking of returned clinical supplies, tracking of individual clinical supply material through production, distribution, return, and destruction; and remote access to inventories for clients.

Xerimis, Inc. is a leader in the field of customized clinical packaging services worldwide, with experience in thousands of trial design projects in all phases of development, including packaging, distribution, return accountability and destruction services. Xerimis' staff provides creative project planning services that can be tailored to virtually any clinical supply issue.

XERIMIS, Inc. Expands Moorestown Facility, Doubles Warehouse Space.
Moorestown, New Jersey (U.S.A), 07 July 2005

Xerimis, Inc. announced the completion of a facility expansion that has doubled the space available for clinical drug product storage, and added dedicated space to important processing tasks.

In addition to the increased warehouse space, the 13,000 square foot expansion included new offices for the growing project management and Quality Assurance teams as well as receiving and quarantine rooms to streamline the reception and inspection of incoming materials. Xerimis also constructed a weighing and sampling room with the ability to maintain strict environmental conditions while drug product is inspected and prepared for processing.

Xerimis, Inc. is a leader in the field of customized clinical packaging services worldwide, with experience in thousands of trial design projects in all phases of development, including packaging, distribution, return accountability and destruction services. Xerimis' staff provides creative project planning services that can be tailored to virtually any clinical supply issue.

XERIMIS, Inc. Announces Frozen Material Capabilities and Expanded Refrigeration Storage.
Moorestown, New Jersey (U.S.A.), 24 July 2004

Xerimis is pleased to announce the addition of frozen material capabilities at -20oC along with the installation of expanded refrigerated storage space (2 to 8oC). Each unit has been fully validated and is linked to a centrally monitored alarm system and a back-up electrical generator for an uninterruptible power supply to ensure the safety and security of critical drug product.

These enhancements to Xerimis' service offerings are in line with the company's managed growth plan. "We are extremely pleased to be able to offer packaging and distribution services of frozen goods and increase our refrigerated materials capacity," said Peter Bernardo, PhD, President and CEO of Xerimis Inc. "Our goal is to offer new services to our clients as we grow while maintaining the best service and response available."

XERIMIS, Inc. Announces Expansion of Facilities and Services.
Moorestown, New Jersey (U.S.A.), 24 April 2003

Xerimis is pleased to announce the completion of its first facility expansion and the introduction of blister packaging capabilities. Both of these enhancements to Xerimis are part of a long-term plan, which is ahead of schedule.

The additional space provides offices for the distribution and finance groups while the majority of the space is designated as warehousing for released clinical supplies. The warehouse space complements the existing facility and improves workflow.

The addition of blister packaging capabilities allows Xerimis to now offer complete primary and secondary packaging services in addition to labeling, assembly, distribution, return accountability and destruction services.

According to Dr. Peter Bernardo, CEO/President, "Our planned growth, both physical plant and staff, have exceeded our expectations. Our senior management has excelled, through their long term experience, in providing quality clinical packaging services, and have allowed Xerimis' growth to proceed as it has". Xerimis is a privately held firm dedicated strictly to the packaging of clinical supplies for pharmaceutical, biotech and clinical research organizations in all phases of development.

XERIMIS, Inc. (USA)and Penn Pharmaceutical Services LTD (UK) Announce Strategic Alliance.
Moorestown, New Jersey (U.S.A.) and Tredegar, South Wales (UK), 03 July 2002

Xerimis Inc. and Penn Pharmaceutical Services Ltd have announced a formal strategic alliance.

The new international pharmaceutical clinical packaging services partnership between Xerimis and Penn Pharmaceutical Services is intended to promote and provide comprehensive customized services throughout the United States and Europe.

"We are extremely pleased to have developed this joint effort and relationship with Penn ," said Peter Bernardo, PhD, President and CEO of Xerimis Inc.

"I am confident that our alliance will further provide our current and future clients with state of the art and fully compliant facilities, assistance with protocol development, interpretation, packaging plan generation and implementation, and it will assure the timely importation of clinical trial materials into Europe. By integrating key services through the combined sites in the United Kingdom and the United States, enhanced capabilities are available to the world's leading pharmaceutical firms," he said.

Commenting on the new developments and expanded services, Craig Rennie, Chief Executive of Penn Pharmaceutical Services Limited, said,

"This alliance will enable Penn to operate more efficiently in the US, expanding our reach beyond our already successful business in Europe and Asia. It enables us to offer our international client base a truly global, fully integrated service and will help us build our rapidly expanding business further in this area. Most importantly in light of the new clinical directive it will open up our unique expertise with importation of clinical trial supplies to the US pharmaceutical industry," he said.

One of the UK's leading integrated pharmaceutical outsourcing companies, Penn, has proven expertise in the provision of fully integrated pharmaceutical services and complete development services from concept and formulation, through clinical trial manufacturing, packaging and distribution, and analytical development, into early stage commercial manufacture.

"Penn offers four Qualified Persons on its Manufacturing License and can perform audits and release products to allow free movement of supplies within the EU - avoiding potential delays and ensuring expedited delivery of supplies to investigator sites," said Rennie.

"In launching this alliance relationship, our primary objectives are two-fold," said Bernardo.

"We intend to build long term, global relationships with our clients and develop successful clinical programs through partnerships in responsibility and planning, while utilizing the experience, enthusiasm and educated skills of our combined staff.

"Xerimis Inc. is a leader in the field of customized clinical packaging services worldwide. Serving pharmaceutical, bio-technology and clinical research organizations of all sizes, and with successful experience derived through thousands of trial design projects, Xerimis' staff provides creative alternative courses of action which can be outlined for virtually any clinical supply issue.

"Working together with Penn Pharmaceutical Services will have a significant effect on handling clinical trials in the European Union and the United States in the manufacture, labeling and importation of investigational medicinal products," he said.

The joint effort will be implemented over the next several months. Initial plans include immediate availability of primary and secondary packaging services and global distribution of clinical supplies.

The recently expanded facility of Xerimis Inc. is located in Moorestown, New Jersey (within 20 minutes of the Philadelphia International Airport and 10 minutes from the New Jersey Turnpike, I-295 and I-95).

Penn Pharmaceutical Services Ltd., founded in 1979, is one of the longest established pharmaceutical services companies in the UK. Based in Tredegar, South Wales, Penn's state of the art facility is less than two hours by train from London Paddington Station and Heathrow Airport.

Visit www.xerimis.com and www.pennpharm.co.uk for the latest service outlines and news of the Xerimis Inc. and Penn Pharmaceutical Services Ltd. Alliance